选择性β1受体阻滞剂在慢性阻塞性肺疾病中的作用进展  

Current use of selective β1-adrenergic receptor blockers in patients with chronic obstructive pulmonary disease

作　　者：汪铮[1] 陈孝谦 马利军[1] 

机构地区：[1]郑州大学人民医院呼吸内科,450003 [2]安徽省第二人民医院呼吸内科,合肥230001

出　　处：《国际呼吸杂志》2013年第13期1006-1011,共6页International Journal of Respiration

摘　　要：慢性阻塞性肺疾病（COPD）患者是心血管疾病的高危人群,常有β受体阻滞剂的应用指征.但由于可能导致气道痉挛,多年来β受体阻滞剂被禁用于COPD合并心血管疾病的治疗.近年来发现,COPD患者使用选择性β1受体阻滞剂并未导致致死性支气管痉挛,还有降低病死率和急性加重次数、改善生活质量等作用.本文就选择性β1受体阻滞剂在COPD患者中的作用进展作一综述.Patients with chronic obstructive pulmonary disease （COPD） are at risk for cardiovascular diseases and may require the usage of a β-adrenergic receptor blocker.However,β-adrenergic receptor blockers have been contraindicated in patients with COPD for inducing bronchoconstriction.More recently,new evidences have shown that the usage of selective β1-adrenergic receptor blockers in COPD patients could reduce the morality and exacerbation frequencies,improve the health quality without causing fatal bronchospasm.This article is to review the current use of selective β1-adrenergic receptor blockers in COPD.

关 键 词：慢性阻塞性肺疾病 Β1受体阻滞剂 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]